VRDN
Viridian TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-03
+
Peers tracked
11
U.S. public peers
Grade Position
Above peers
vs peer average
VRDN vs peer average
76/100
VRDN vs. peer average (B vs. D)
Grade spread
B 1 · C 2 · D 4 · F 1
Graded peers loaded
Coverage
9 graded
82% of tracked
Peer overview
APLS is the first available peer comparator.
Apellis — similar ophthalmology focus and clinical‑stage commercialization pathway.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
VRDN
Viridian Therapeutics
APLS
Peer
Grade
B
-
Momentum
28
-
Value
41
-
Sentiment
100
-
Setup Bias
Net Neutral
-
Market Cap
-
-
Posture
Constructive
Unrated
Grade position vs APLS
VRDN / APLS
Grade Position
Above peers
VRDN vs. peer average (B vs. D)
76/100
Momentum
28
-Value
41
-Sentiment
100
-Rotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs VRDN
APLS is the first peer returned for this comparison set.